Clinical Trial Search

Primary: Number of Participants Improved as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2) — 11; 3 participants

Primary: Weight Change — 6.5; 6.3 kg

Primary: Number of Subjects Who Passed the Voiding Trial After a Midurethral Sling — 31; 32 Participants

Primary: Number of Participants With Post-baseline Clinically Significant Findings in Physical Examinations — 0; 0 participants

Primary: Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set — -0.73; -0.90 log10 copies/mL — p=0.72

Primary: Number of Participants With Treatment Emergent Adverse Events — 3; 1; 1; 1 Participants

Primary: The Number of Participants Who Achieved a Hemoglobin A1C <7% — 5; 12 Participants

Primary: Time-Normalized Number of Attacks (NNA) for Participants During a Treatment Period — 1.611; 3.931 Number of attacks — p=<0.0001

Primary: Adverse Events by Severity — 20; 8; 25; 8 Participants

Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236

Primary: Number of Patients With Treatment-emergent Adverse Events — 3; 3; 6; 3 Participants

Primary: Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline — 2.84; 3.03; 3.36; 1.81 log10 IU/mL

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging — 8.8; 4.9 Months — p=<0.00001

Primary: Highest Grade of Reactogenicity Events in the Adult Cohort: Vaccination 1 — 11; 12; 22; 1 Participants

Primary: Baseline Quantitative Sensory Testing (QST) — 39.7063; 39.8286; 43.9563; 45.2036 Degrees Celsius